Wuhan Hiteck Biological Pharma Co Ltd (300683)

Currency in CNY
52.02
-2.15(-3.97%)
Closed·
300683 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
300683 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
48.5155.27
52 wk Range
19.0060.19
Key Statistics
Bid/Ask
51.95 / 52.02
Prev. Close
54.17
Open
51.75
Day's Range
48.51-55.27
52 wk Range
19-60.19
Volume
16.79M
Average Volume (3m)
6.28M
1-Year Change
127.58%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300683 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Wuhan Hiteck Biological Pharma Co Ltd Company Profile

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kit for a –Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs; and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

Employees
1309
Market
China

Compare 300683 to Peers and Sector

Metrics to compare
300683
Peers
Sector
Relationship
P/E Ratio
−106.3x40.1x−0.5x
PEG Ratio
−2.13−1.310.00
Price/Book
3.0x2.0x2.6x
Price / LTM Sales
10.5x7.0x3.3x
Upside (Analyst Target)
-3.9%43.5%
Fair Value Upside
Unlock11.8%6.9%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.51%
Dividend Yield
0.25%
Industry Median 1.51%
Annualised payout
0.13
Paid annually
5-Years Growth
-4.07%
Growth Streak

Earnings

Latest Release
Apr 20, 2025
EPS / Forecast
-0.11 / --
Revenue / Forecast
156.67M / --
EPS Revisions
Last 90 days

300683 Income Statement

FAQ

What Stock Exchange Does Wuhan Hiteck Biological Pharma Trade On?

Wuhan Hiteck Biological Pharma is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Wuhan Hiteck Biological Pharma?

The stock symbol for Wuhan Hiteck Biological Pharma is "300683."

What Is the Wuhan Hiteck Biological Pharma Market Cap?

As of today, Wuhan Hiteck Biological Pharma market cap is 6.81B.

What Is Wuhan Hiteck Biological Pharma's Earnings Per Share (TTM)?

The Wuhan Hiteck Biological Pharma EPS (TTM) is -0.51.

From a Technical Analysis Perspective, Is 300683 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Wuhan Hiteck Biological Pharma Stock Split?

Wuhan Hiteck Biological Pharma has split 0 times.

How Many Employees Does Wuhan Hiteck Biological Pharma Have?

Wuhan Hiteck Biological Pharma has 1309 employees.

What is the current trading status of Wuhan Hiteck Biological Pharma (300683)?

As of 07 Aug 2025, Wuhan Hiteck Biological Pharma (300683) is trading at a price of 52.02, with a previous close of 54.17. The stock has fluctuated within a day range of 48.51 to 55.27, while its 52-week range spans from 19.00 to 60.19.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.